Lisata Therapeutics Inc (LSTA)

[akasidney86]

Just got a chance to listen to the presentation, which in combo with the Hitachi news, is all good. Most interesting, to me, was the question at about 37:00 minutes about operating break-even forecast for 2016.

For reasons I don't really understand, they (CLBS management) remain evasive about this issue. However, they did say that as a base number, the 2015 $8m quarterly burn could be used as a cost basis going forwards. They then added that off that $8m there would be savings from the elimination of the CLBS20 P-III trial and further savings from a serious effort to cut general company expenses, while there would be increases due to the build-out of the PCT labs (although the majority of the programmed $6m, $3.2m, has already be expensed to 2015).

My bottom line: if they are able to reduce the 2015 burn rate even 10%, with the forecast earnings of OVER $30m (high confidence, based upon contracts in hand), the company is in the black in 2016, even with an ongoing P-II type I diabetes trial moving forwards.